Half of all prostate cancers are caused by the TMPRSS2-ERG genefusion, which enables androgens to drive expression of the normally silent E26 transformation-specific (ETS) transcription factor ERG in prostate cells 1, 2 . Recent genomic landscape studies of such cancers [3] [4] [5] [6] [7] [8] have reported recurrent point mutations and focal deletions of another ETS member, the ETS2 repressor factor ERF
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. Here we show these ERF mutations cause decreased protein stability and mostly occur in tumours without ERG upregulation. ERF loss recapitulates the morphological and phenotypic features of ERG gain in normal mouse prostate cells, including expansion of the androgen receptor transcriptional repertoire, and ERF has tumour suppressor activity in the same genetic background of Pten loss that yields oncogenic activity by ERG. In the more common scenario of ERG upregulation, chromatin immunoprecipitation followed by sequencing indicates that ERG inhibits the ability of ERF to bind DNA at consensus ETS sites both in normal and in cancerous prostate cells. Consistent with a competition model, ERF overexpression blocks ERG-dependent tumour growth, and ERF loss rescues TMPRSS2-ERG-positive prostate cancer cells from ERG dependency. Collectively, these data provide evidence that the oncogenicity of ERG is mediated, in part, by competition with ERF and they raise the larger question of whether other gain-of-function oncogenic transcription factors might also inactivate endogenous tumour suppressors.
Recent exome sequencing revealed that 3% of patients in the SU2C-294 metastatic prostate cancer cohort 3 (Extended Data Fig. 1a ) have somatic point mutations, but not gene fusions, involving the ETS member ERF. ERF was one of a small number of genes whose mutation frequency and predicted functional impact reached significance by the MutSig algorithm 10 . Loss-of-function ERF germline mutations and lower ERF expression have been previously implicated in the disease complex craniosynostosis 11 . Notably, the DNA-binding ETS domain of ERF is most similar to the ERG subfamily 12 . However, unlike oncogenic ETS factors 12 , ERF possesses a transferable carboxy-terminal domain that mediates transcriptional repression 9 . We queried additional prostate cancer genome cohorts (n = 930 patients) [4] [5] [6] [7] [8] (Extended Data Fig. 1a ) and found further evidence of ERF mutations (Fig. 1a ) in 1-3% of patients. The mutations include the specific K401fs and G299fs loss-of-function truncations also found in craniosynostosis families 11 , as well as similar missense mutations in the ETS domain. Mapping of these ETS missense mutations onto the known crystal structure of ERG 13 revealed that the altered residues are located within conserved helices (Extended Data Fig. 1b) , with four of the five conserved mutations predicted to be destabilizing 14 . Expression of complementary DNAs (cDNAs) containing the ETS missense or truncating mutations in LNCaP prostate cancer cells led to reduced ERF steady-state levels relative to wild-type ERF despite robust messenger RNA (mRNA) expression (Extended Data Fig. 1c, d ), in agreement with the craniosynostosis studies 11 . In addition, only fulllength ERF was detected following immunoprecipitation in prostate cancer cells possessing an endogenous heterozygous K401fs allele 5 (Extended Data Fig. 1e) . Consistent with destabilization, we were unable to isolate mutant ERF ETS domains through recombinant expression in bacteria, whereas appreciable amounts of wild-type ERF ETS were obtained (Extended Data Fig. 1f ).
In addition to destabilizing mutations, we observed remarkably narrow deletions of the ERF locus within the TCGA-333 primary tumour cohort 4 (Fig. 1b) . Median ERF expression in those tumours containing focal hemizygous deletions is lower than in normal prostate and diploid ERF tumours (Extended Data Fig. 2a , P = 0.019). Intriguingly, tumours with either ERF mutations or focal deletions are mostly exclusive to TMPRSS2-ERG-negative tumours ( Fig. 1c , P = 0.022). Metastatic tumours in the SU2C-294 cohort 3 containing ERF point mutations are also mostly exclusive to those without upregulated ERG, but this distinction does not reach statistical significance (Extended Data Fig. 2b , P = 0.066).
The near complete lack of ERF mutations in tumours with TMPRSS2-ERG fusions led us to investigate whether ERF loss recapitulates the phenotype of ERG gain. ERG is not expressed in benign prostate epithelium and displays potent oncogenicity in a mouse Pten −/− background 2, 15 . On the other hand, ERF is endogenously expressed in normal prostate (Extended Data Fig. 2a ). To determine whether its loss yields a phenotype similar to ERG gain, we infected prostate organoids 16 derived from Pten +/+ and Pten −/− mice 15 with short hairpin RNA (shRNA) targeting mouse Erf (shErf_m) (Extended Data Fig. 3a) . The Pten +/+ shErf_m organoids acquired morphological characteristics of ERG overexpression 17 : they formed single-cell luminal structures lacking basal cells (Fig. 2a) , and profiling by RNA sequencing (RNA-seq) demonstrated profound loss of expression of most basal signature genes 18 ( Fig. 2b and Extended Data Fig. 2b-d) . Consistent with these changes 17, 18 , RNA-seq profiling revealed significant enrichment for genes whose expression is upregulated by androgen in human prostate cancer cells (Extended Data Fig. 2c, e) . The Pten −/− organoids 16 infected with shErf_m also demonstrated a marked luminal shift ( Fig. 2a) and were able to form tumours when grafted back into mice, recapitulating the phenotype of ERG overexpression 15 ( Fig. 2c) . To assess the impact of ERF loss in the half of human prostate cancers that lack ERG expression similarly to normal prostate, we infected a human cancer-derived cell line lacking the TMPRSS2-ERG gene fusion, CWR22Pc, with shRNA targeting ERF (Extended Data Fig. 4a ) and analysed its androgen transcriptome. We observed both an increase in the number of differentially expressed androgen receptor target genes and in the magnitude of the expression changes (Extended Data Fig. 4b ), despite no alteration of androgen receptor mRNA or protein levels (Extended Data Fig. 4a, c) . Next, we interrogated the mRNA expression profiles of the primary and metastatic human prostate cohorts TCGA-333 and SU2C-150 (refs 3, 4), respectively. In agreement with our functional studies, ERF mRNA levels are inversely correlated with two androgen transcriptional activity signatures 19, 20 , both in normal human prostate and in all primary tumour subtypes ( Fig. 2d and Extended Data Fig. 5a ). This reciprocal association is also observed in metastatic cancers if the analysis is limited to tumours without amplification of or mutations in the AR gene, which encodes the androgen receptor (Extended Data Fig. 5b ). The fact that reduced ERF expression enhances androgen receptor transcriptional output even in the absence of mutation or deletion, raises the possibility that ERF may have a broader role in prostate oncogenesis.
The inverse correlation between ERF mRNA level and the androgen receptor signature is also observed in the half of prostate cancers that possess the TMPRSS2-ERG fusion (Fig. 2d ), suggesting that ERF may have an androgen receptor repressive function in this subtype as well. To investigate this possibility, the expression of ERG or ERF was separately inhibited via shRNA (Extended Data Fig. 6a , b) in the ERG-fusion-positive VCaP cell line and the androgen transcriptome analysed as before. Consistent with earlier work 15 , inhibition of ERG expression ('ERG-low') resulted in a contracted androgen transcriptome compared with the wild-type state ('ERG-high'). Conversely, ERF inhibition increased the change in expression of androgen receptor target genes and doubled the size of the androgen transcriptome ( Fig. 3a and Extended Data Fig. 7 ). ERF and ERG knockdown had no effect on each other's expression, on androgen receptor protein levels, or on androgen receptor subcellular localization (Extended Data Fig. 6c, d) .
Given the similarity of their ETS domains 12 (Extended Data Fig. 1b) , we postulated that the opposing effects of ERF and ERG on androgen signalling could be explained by competition for androgen-receptorassociated ETS binding sites, which we investigated by ERF chromatin immunoprecipitation followed by sequencing (ChIP-seq) in the ERGhigh and ERG-low states ( Fig. 3b and Extended Data Fig. 8) . De novo motif analysis identified the canonical ETS motif as the primary ERF binding site, with 2,793 binding sites in the ERG-high condition ( (1) and (2) in Fig. 3b) . Remarkably, an additional 26,714 ERF binding sites were observed in the ERG-low state, 76% of which were bound by ERG before ERG knockdown ( (1) and (3) in Fig. 3b , and Extended Data Fig. 8d) . Furthermore, the ChIP-seq signal intensity of the smaller number of ERF peaks observed in the ERG-high state was increased in the ERG-low state in almost all cases (Extended Data Fig. 8c, e) . Finally, ERF peaks in the ERG-low state largely overlap with androgen receptor binding peaks ( (3) in Fig. 3b ), as previously reported for ERG 15 , and are exemplified by PLEKHD1 and SCD 20 ( (4) in Fig. 3b , and Extended Data Fig. 8f ). In the ERG-high state, both genes have promi nent androgen-receptor-and ERG-associated binding but only limited ERF binding. However, in the ERG-low state, ERF binding is substantially increased in parallel with a decrease in their androgeninduced expression (Fig. 3a) . 
(1) Given the role that ERF also plays in benign prostate cells, we performed ChIP-seq to confirm that ERF binds ETS sites in the normal prostate organoids (Fig. 3c) . Moreover, transient overexpression of ERG led to a significant decrease of ERF chromatin occupancy (Fig. 3c and Extended Data Fig. 9 ), consistent with the competition for binding also seen in VCaP cancer cells. We explored the overlap between androgen receptor and ERF sites in normal prostate organoids by androgen receptor ChIP-seq and found 28% of the ERF sites overlap with androgen receptor binding sites ( (3) in Fig. 3c ). This was lower than observed in the ERG-positive VCaP tumour cells, consistent with differences in androgen receptor chromatin occupancy between normal prostate and cancer 21 . We next asked whether ERF could modulate oncogenicity mediated by ERG expression. First, we used CRISPR-Cas9 (clustered regularly interspaced short palindromic repeats and CRISPR-associated protein 9) to partially delete ERF (sgErf) in pooled mouse Pten
ERG/ERG organoids (Extended Data Fig. 10a ), which require ERG to form tumours 15 . The sgErf organoids formed tumours more rapidly than those infected with a non-targeting CRISPR (Fig. 4a) . Likewise, induction of human ERF expression in these cells blocked androgen-dependent gene expression (Extended Data Fig. 10b , c) and prevented tumour formation (Fig. 4b) . To address the role of ERF in transformation of human prostate cancer cells, we predicted that the anti-proliferative effect of ERG knockdown in ERG-positive cells 22 should be rescued by concurrent knockdown of ERF. Consistent with previous findings 22 , partial ERG deletion via CRISPRCas9 led to a complete halt of proliferation ( Fig. 4c and Extended Data Fig. 10d) . Strikingly, stable shRNA knockdown of ERF before partial ERG deletion rescued cells from ERG-dependent prolife ration and survival. Moreover, ERF knockdown restored the constricted androgen transcriptome conferred by ERG loss, including restoration of SCD and PLEKHD1 mRNA upregulation (Fig. 4d and Extended Data Fig. 10e) .
We propose that loss of ERF activity, either by rare genomic lossof-function mutations or more commonly by competition with the TMPRSS2-ERG oncogenic gene product, leads to activation of the androgen receptor pathway and prostate cancer (Fig. 4e) . The consequences of ERF loss and ERG gain have many common functional consequences, including regulation of luminal morphology, expanded activity of androgen receptor, and an ability to form tumours in a Pten −/− background. Such similarities are consistent with their mutual exclusivity and the ability of ERF loss to rescue ERG-positive prostate cancer cells from ERG dependency. On the other hand, the fact that ERG translocations are more common than ERF mutant tumours (46% versus 4%, respectively, in the TCGA-333 primary prostate cancer cohort) raises the possibility that ERG has additional gain-offunction activities that favour oncogenic transformation, such as an intrinsic androgen receptor reprogramming activity 15, 21 . A related but unresolved question is whether the oncogenic phenotype of ERF loss is simply due to loss of repression, or to gain-of-function conferred by competition with an unknown endogenous 'positive' ETS factor. Understanding ETS competition has implications also for ETS-driven leukaemias and sarcomas, and perhaps more broadly for other oncogenic transcription factors for which corresponding loss-of-function mutations in cognate repressors might be considered.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. , Eliezer M. Van Allen 11, 12 , Yi-Mi Wu 9, 10 , Nikolaus Schultz 15 . Isolation and growth of MSK-PCa3 cells were described previously 5 . LNCaP cells were obtained from American Type Culture Collection (ATCC) and maintained as previously described 23 . CWR22Pc were a gift from M. Nevalainen and maintained as described previously 23 . For CWR22Pc cells specifically, charcoal-stripped media was used for transcriptome analysis. VCaP cells were obtained from ATCC (CRL-2876) and maintained as previously described 23 . Cells were confirmed to be free of mycoplasma using a Lonza detection kit (LT07-318). Cell line authentication was confirmed by SNP fingerprinting and hallmark gene-fusions/mutations were identified by deep sequencing. Prostate cancer tumour profiling. Profiles of the various cohorts 3-7 outlined in Extended Data Fig. 1a can be explored in the cBioPortal for Cancer Genomics (http://www.cbioportal.org). The TCGA data can also be accessed through the Broad Institute FireBrowse portal (http://firebrowse.org/?cohort= PRAD), and the ICGC-CRUK Prostate Adenocarcinoma data can be accessed through the ICGC Portal (https://icgc.org/icgc/cgp/70/508/71331). In Fig. 1a and Extended Data  Fig. 2b , we report four previously unpublished mutations in ERF from a larger Stand Up to Cancer 3 (SU2C) cohort that will be described in the future. Organoid histology and xenografts. Organoids were infected with the indicated lentivirus, selected with puromycin and further selected with FACS. For histology and immunohistochemistry, organoids were processed as described previously 5, 16 . Immunohistochemistry was performed using a Ventana BenchMark ULTRA. The anti-CK8/18 antibody was purchased from Abcam (ab53280). In vivo xenograft experiments were performed as described previously 23 , using 7-week-old male C.B17 SCID mice (Taconic): one million cells were injected into the flank for a total of ten tumours per shRNA and cell type. Once tumours were palpable, tumour volume was measured weekly using a Peira TM900 system (Peira, Belgium). The maximal tumour volume permitted by our Institutional Animal Care and Use Committee under protocol 06-07-012 was 2 cm 3 , beyond which mice were euthanized. . CRISPR-Cas9 experiments were performed by infection and puromycin selection of cells with lentivirus containing the lentiCRISPRv2 vector gifted by F. Zhang (Addgene plasmid 52961) containing the following guide sequences chosen via the http://www.genome-engineering.org website: sgERG (GATAACTCTGCGCTCGTTCG), sgERFm (CCTGCCAAGCGATGACGCCC), and previously described sgNT 26 . Overexpression of cDNAs was achieved by the constitutive or Tet-inducible pLV-based lentiviral expression system. Transcription analysis. RNA was extracted from cell lines using an RNeasy Kit (Qiagen). For quantitative PCR with reverse transcription (RT-qPCR) and RNA-seq experiments, cells were plated in triplicate per condition/infected construct at the beginning of the assay (duplicate for mouse organoid RNA-seq), and thereafter replicates were processed independently. Error bars for bar graphs indicate s.e.m. for the biological replicates. DHT (Sigma) (or DMSO vehicle) was added at 1 nM, and treatments were performed for 16 h. For RT-qPCR, cDNA was generated with a High Capacity cDNA Reverse Transcription Kit (Applied Biosystems). Data were quantified relative to β -actin or GAPDH expression, and relative expression was plotted. Primers for human and mouse ERF were purchased from Qiagen. Other qPCR primers were as follows: androgen receptor (F: CCATCTTGTCGTCAATGTTATGAAGC, R: AGCTTCTGGGTTGTCTCCTCAGTGG), ERG (F: CAAAACTCTCCA CGGTTAATGC, R: ACCGGTCCAGGCTGATCT).
For RNA-seq, library preparation and sequencing were performed by the Memorial Sloan Kettering Cancer Center Integrated Genomics Operation Core using Illumina HiSeq with 50 base pair (bp) paired-end reads, with approximately 30 million reads generated for each sample. The output data (FASTQ files) were mapped to the target genome (UCSC HG19 or UCSC MM10) using the rnaStar aligner, which mapped reads genomically and resolved reads across splice junctions.
The 2-pass mapping method was used in which the reads were mapped twice. The first mapping pass used a list of known annotated junctions from Ensembl. Novel junctions found in the first pass were then added to the known junctions and a second mapping pass was done (on the second pass the RemoveNoncanonical flag was used). After mapping, we post-processed the output SAM files using the PICARD tools to add read groups, with AddOrReplaceReadGroups, which sorted the file and converted it to the compressed BAM format. We then computed the expression count matrix from the mapped reads using HTSeq (http://www-huber. embl.de/users/anders/HTSeq). The raw count matrix generated by HTSeq was then processed using the R/Bioconductor package DESeq (http://www-huber.embl. de/users/anders/DESeq/), which was used both to normalize the full dataset and to analyse differential expression between sample groups. Androgen-regulated genes were defined as a twofold difference, false discovery rate (FDR) < 0.05 with 1 nM DHT treatment for 16 h DHT. For GSEA, statistical analysis was performed with publicly available software from the Broad Institute (http://www.broadinstitute. org/gsea/index.jsp). ChIP. Chromatin processing, as well as anti-androgen receptor, anti-ERG, and immunoglobulin-G ChIP were described previously 15 . ERF ChIP was performed with anti-ERF antibody (Pierce PA5-30237). For ChIP-qPCR, the ETS2 promoter primers (forward: TTACTTCCTCCAGAGACTGACGA; reverse: CGCCGGCCAGAGACGAT) were used. The PSA upstream sequence lacking the ERF motif or androgen receptor binding motif was described previously 27 . For ChIP-seq, library preparation and RNA-seq were performed by the Memorial Sloan Kettering Cancer Center Integrated Genomics Operation Core using Illumina HiSeq with 50-bp paired-end reads. The reads were aligned to the human genome (hg19, build 37) or the mouse genome (mm10, build 38) using the program BWA (default parameters) within the PEMapper. The software MACS2 (ref. 28) (-q 0.1) was used for peak identification with data from ChIP input DNAs as controls. Peaks of sizes > 100 bp and with at least one base pair covered by > 15 reads were selected as the final peaks. Peaks from different conditions were merged to obtain non-overlapping genomic regions, which were then used to determine conditional specific binding. Overlapped peaks were defined as those sharing at least one base pair. Two replicates were performed per condition, and peaks called in both replicates were used as the final peaks for each condition. To generate heat maps depicting ERF ChIP-seq read density in ± 2 kilobase regions of the ERF peak summits, the same number of ChIP-seq reads from different conditions were loaded into the software seqMINER 29 , and the resulting read density matrices were sorted by the read densities in the ERG-low condition in VCaP cells or wild-type condition for the mouse prostate organoids, before colouring. The criteria for assigning peaks to genes have been described previously 30, 31 . The MEME-ChIP software 32 was applied to 300-bp sequences around the peak summits for motif discovery. Immunoprecipitation and western blot analysis. Protein was extracted from cell lines using M-PER Reagent (Thermo Scientific) and quantified by BCA Protein Assay (ThermoFisher Scientific). Nuclear/cytoplasmic fractionation was achieved with an NE-PER kit (ThermoFisher Scientific). ERF immunoprecipitation was performed with anti-ERF antibody (Pierce PA5-30237). Western blots were imaged using the fluorometric-based LiCor system, using primary antibodies against ERF (Santa Cruz sc-15435 or Abcam ab61108) and PTEN (Cell Signaling 9188). Western blotting for androgen receptor, ERG, GAPDH, and actin was described previously 15 . In vitro growth assay. Cells were plated in triplicate and assayed at the time points indicated using CellTiter-Glo (Promega). Viability was plotted normalized to day 1. Error bars indicate s.e.m. Statistics. Mutual exclusivity in the cBio Oncoprints was calculated using a twotailed Fisher's exact test. For RT-qPCR and RNA-seq experiments, cells were plated in triplicate per condition/infected construct at the beginning of the assay (duplicate for mouse organoid RNA-seq), and thereafter replicates were processed independently. RT-qPCR bar graphs are plotted as mean ± s.e.m. For RNA-seq, differentially expressed genes were defined as a twofold difference, FDR < 0.05 of DESeq-normalized expression. For GSEA, statistical analysis was performed with publicly available software from the Broad Institute (http://www.broadinstitute. org/gsea/index.jsp). For the correlation of the androgen transcriptional signatures with ERF mRNA in human tumours, statistical significance of correlations was calculated by Spearman's test. Mouse graft experiments consisted of ten tumours per condition, and a Mann-Whitney test was used in Fig. 4 to analyse differences in tumour volume. The sample size estimate was based on our experience with previous experiments 5, 15, 23 . No formal randomization process was used to assign mice to a given organoid injection, and experimenters were not blinded. Data availability. All data are available from the authors upon reasonable request. The described RNA-seq and ChIP-seq data have been deposited in the Gene Expression Omnibus under accession number GSE83653.
